Grifols Purchases Novartis Transfusion Diagnostics Unit
Grifols expands and diversifies portfolio with acquisition of diagnostic business.
Grifols, a producer of plasma therapies, and Novartis have announced that Grifols will acquire the transfusion diagnostics unit of Novartis for $1.68 billion, according to a Grifols press release. The transaction is part of Grifols’ growth strategy of complementing its range of plasma protein therapies with other diagnostic products and services (Diagnostic Division). Assets acquired in the transaction include patents, brands, licenses, and royalties as well as a production plant in Emeryville, CA, and commercial offices in the United States, Switzerland, and Hong Kong (for the Asia-Pacific region) among others.
Grifols plans on expanding its portfolio by including Novartis’ diagnostic products for transfusion medicine and immunology, including its highly innovative, market-leading Nucleic Acid Amplification Techniques (NAT) technology, instrumentation, and equipment for blood screening, specific software, and reagents. The company hopes this strategic operation will strengthen Grifols’ Diagnostic Division, particularly in the US.
The company also expects Novartis’ diagnostic business, which focuses on guaranteeing the safety of blood donations for transfusion or to be used in the plasma fractionating industry, to complement Grifols’ existing bioscience division (plasma proteins). The company hopes to provide solutions for blood and plasma donor centers, with the most complete product portfolio in the immunohematology field: gel cards, multicard, and the new genotyping technology from Progenika.
“The acquisition of Novartis’ diagnostic business is a step further into our vision to become a world leader also in the diagnostics field,” said Victor Grifols, president and CEO of Grifols, in the press release. “To achieve this we knew we needed a significant presence in United States. We initiated the process in the Bioscience area in 2003 with the acquisition of the ATC assets and continued with the Talecris transaction in 2011. During the last two years the Diagnostic Division has been preparing for this step, especially in the immunohematology activities”
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
